Vaxxinity, Inc. (VAXX)
- Previous Close
0.1214 - Open
0.1210 - Bid --
- Ask 0.1170 x 100
- Day's Range
0.1075 - 0.1250 - 52 Week Range
0.1075 - 3.1000 - Volume
1,999,747 - Avg. Volume
725,129 - Market Cap (intraday)
14.779M - Beta (5Y Monthly) 2.40
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4500 - Earnings Date May 7, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
15.00
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and VXX-301, an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; VXX-401 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Merritt Island, Florida.
www.vaxxinity.comRecent News: VAXX
Performance Overview: VAXX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VAXX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VAXX
Valuation Measures
Market Cap
14.78M
Enterprise Value
-448.22k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.10
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
0.01
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-48.34%
Return on Equity (ttm)
-150.65%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-56.93M
Diluted EPS (ttm)
-0.4500
Balance Sheet and Cash Flow
Total Cash (mrq)
30.64M
Total Debt/Equity (mrq)
113.12%
Levered Free Cash Flow (ttm)
-37.38M